RU2018117944A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2018117944A3 RU2018117944A3 RU2018117944A RU2018117944A RU2018117944A3 RU 2018117944 A3 RU2018117944 A3 RU 2018117944A3 RU 2018117944 A RU2018117944 A RU 2018117944A RU 2018117944 A RU2018117944 A RU 2018117944A RU 2018117944 A3 RU2018117944 A3 RU 2018117944A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2517/00—Cells related to new breeds of animals
- C12N2517/02—Cells from transgenic animals
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Environmental Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562258181P | 2015-11-20 | 2015-11-20 | |
| US62/258,181 | 2015-11-20 | ||
| US201662370430P | 2016-08-03 | 2016-08-03 | |
| US62/370,430 | 2016-08-03 | ||
| PCT/US2016/062733 WO2017087780A1 (en) | 2015-11-20 | 2016-11-18 | Non-human animals having a humanized lymphocyte-activation gene 3 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018117944A RU2018117944A (ru) | 2019-12-20 |
| RU2018117944A3 true RU2018117944A3 (cg-RX-API-DMAC7.html) | 2020-04-06 |
| RU2745403C2 RU2745403C2 (ru) | 2021-03-24 |
Family
ID=57543170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018117944A RU2745403C2 (ru) | 2015-11-20 | 2016-11-18 | Животные, отличные от человека, имеющие гуманизированный ген активации лимфоцитов-3 |
Country Status (26)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3230320T (lt) | 2014-12-09 | 2021-01-11 | Regeneron Pharmaceuticals, Inc. | Gyvūnai, išskyrus žmogų, turintys humanizuotą diferenciacijos klasterio 274 geną |
| LT3376857T (lt) | 2015-11-20 | 2021-06-25 | Regeneron Pharmaceuticals, Inc. | Gyvūnai, ne žmonės, turintys humanizuotą limfocitų aktyvavimo geną |
| CN109068621B (zh) | 2016-02-29 | 2021-07-20 | 再生元制药公司 | 具有人源化的tmprss基因的啮齿类动物 |
| WO2018001241A1 (zh) | 2016-06-28 | 2018-01-04 | 北京百奥赛图基因生物技术有限公司 | 一种pd-1基因修饰人源化动物模型的构建方法及其应用 |
| CN107815468B (zh) | 2016-08-31 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化基因改造动物模型的制备方法及应用 |
| CN108070613B (zh) * | 2016-11-11 | 2020-03-13 | 百奥赛图江苏基因生物技术有限公司 | 人源化基因改造动物模型的制备方法及应用 |
| WO2018086583A1 (en) * | 2016-11-11 | 2018-05-17 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric lag-3 |
| SG11201911886PA (en) * | 2017-06-27 | 2020-01-30 | Regeneron Pharma | Non-human animals comprising a humanized asgr1 locus |
| US11021719B2 (en) | 2017-07-31 | 2021-06-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for assessing CRISPER/Cas-mediated disruption or excision and CRISPR/Cas-induced recombination with an exogenous donor nucleic acid in vivo |
| ES3033963T3 (en) | 2017-07-31 | 2025-08-11 | Regeneron Pharma | Method of testing the ability of a crispr/cas9 nuclease to modify a target genomic locus in vivo, by making use of a cas-transgenic mouse or rat which comprises a cas9 expression cassette in its genome |
| WO2019067875A1 (en) | 2017-09-29 | 2019-04-04 | Regeneron Pharmaceuticals, Inc. | NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE |
| WO2019072241A1 (en) * | 2017-10-13 | 2019-04-18 | Beijing Biocytogen Co., Ltd | NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC |
| CN109666701B (zh) * | 2017-10-13 | 2021-08-24 | 百奥赛图(北京)医药科技股份有限公司 | 一种pd-1基因修饰人源化动物模型的构建方法及其应用 |
| AU2018375796B2 (en) | 2017-11-30 | 2024-11-21 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized TRKB locus |
| WO2019183123A1 (en) | 2018-03-19 | 2019-09-26 | Regeneron Pharmaceuticals, Inc. | Transcription modulation in animals using crispr/cas systems |
| AU2019242586B2 (en) | 2018-03-26 | 2025-09-11 | Regeneron Pharmaceuticals, Inc. | Humanized rodents for testing therapeutic agents |
| PL3823443T3 (pl) | 2018-07-16 | 2024-09-23 | Regeneron Pharmaceuticals, Inc. | Modele gryzoni z chorobą ditra i ich zastosowania |
| WO2020125763A1 (en) * | 2018-12-20 | 2020-06-25 | Biocytogen Jiangsu Co., Ltd. | Genetically modified non-human animal with human or chimeric lag3 |
| CN109929875B (zh) * | 2019-03-12 | 2021-02-19 | 江苏集萃药康生物科技股份有限公司 | 一种lag3基因人源化动物模型的构建方法及其应用 |
| IL286905B2 (en) | 2019-04-04 | 2024-06-01 | Regeneron Pharma | Non-human animals containing the human coagulation factor 12 locus |
| WO2020247452A1 (en) | 2019-06-04 | 2020-12-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use |
| SG11202111256XA (en) | 2019-06-07 | 2021-11-29 | Regeneron Pharma | Non-human animals comprising a humanized albumin locus |
| US12250931B2 (en) | 2020-01-28 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Genetically modified mouse with a humanized PNPLA3 gene and methods of use |
| EP4138550A1 (en) * | 2020-04-21 | 2023-03-01 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized cxcl13 gene |
| WO2025163140A1 (en) * | 2024-02-02 | 2025-08-07 | Vacara Ab | Physiologic humanized mice for studies of mhc class ii function |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA953629B (en) * | 1994-05-06 | 1996-11-05 | Roussy Inst Gustave | Soluble polypeptidic fragments of lag-3 protein method of production thereof therapeutic composition anti-idiotype antibodies |
| US5670356A (en) | 1994-12-12 | 1997-09-23 | Promega Corporation | Modified luciferase |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| EP1897548B2 (en) * | 2003-02-28 | 2024-05-22 | The Johns Hopkins University | T cell regulation |
| PL1802193T3 (pl) | 2004-10-19 | 2014-09-30 | Regeneron Pharma | Sposób wytwarzania myszy homozygotycznej pod względem modyfikacji genetycznej |
| AR072999A1 (es) * | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| WO2011020014A1 (en) | 2009-08-14 | 2011-02-17 | Regeneron Pharmaceuticals, Inc. | Promoter-regulated differentiation-dependent self-deleting cassette |
| DK3417701T3 (da) | 2009-10-06 | 2022-03-14 | Regeneron Pharma | Genmodificerede mus og indpodning |
| US20130061340A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc. | Identification and Enrichment of Cell Subpopulations |
| MX338971B (es) | 2011-02-15 | 2016-05-06 | Inst Res Biomedicine Irb | Ratones de m-csf humanizada. |
| LT3590332T (lt) | 2011-10-28 | 2022-08-10 | Regeneron Pharmaceuticals, Inc. | Genetiškai modifikuotos pelės, ekspresuojančios chimerines pagrindinio audinių dermės komplekso (mhc) ii molekules |
| LT3262932T (lt) | 2011-10-28 | 2019-08-26 | Regeneron Pharmaceuticals, Inc. | Pelės su genetiškai modifikuotu pagrindiniu histosuderinamumo kompleksu |
| IN2014CN03890A (cg-RX-API-DMAC7.html) | 2011-10-28 | 2015-10-16 | Regeneron Pharma | |
| WO2013063556A1 (en) | 2011-10-28 | 2013-05-02 | Regeneron Pharmaceuticals, Inc. | Humanized il-6 and il-6 receptor |
| UY34887A (es) * | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN120718856A (zh) | 2012-09-07 | 2025-09-30 | 再生元制药公司 | 经遗传修饰的非人动物及其使用方法 |
| KR102207767B1 (ko) * | 2012-09-17 | 2021-01-26 | 갈렉틴 테라퓨틱스, 인크. | 암 치료에서의 특이적 면역요법을 강화하는 방법 |
| ES2748662T3 (es) | 2012-11-05 | 2020-03-17 | Institute For Res In Biomedicine Irb | Roedores inmunodeficientes modificados genéticamente y métodos de uso de los mismos |
| SMT201900429T1 (it) | 2013-02-20 | 2019-09-09 | Regeneron Pharma | Topi esprimenti co-recettori umanizzati linfociti t |
| EP2958937B1 (en) | 2013-02-22 | 2018-08-15 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized major histocompatibility complex |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| HUE040575T2 (hu) | 2013-04-16 | 2019-03-28 | Regeneron Pharma | A patkány genom célzott módosítása |
| DK4269430T3 (da) | 2013-09-23 | 2025-08-18 | Regeneron Pharma | Ikke-menneskelige dyr, der har et humaniseret signalregulerende proteingen |
| MY183188A (en) | 2013-11-19 | 2021-02-18 | Regeneron Pharma | Non-human animals having a humanized b-cell activating factor gene |
| ES2794942T3 (es) | 2014-04-08 | 2020-11-19 | Regeneron Pharma | Animales no humanos que tienen receptores Fc-gamma humanizados |
| NO2785538T3 (cg-RX-API-DMAC7.html) | 2014-05-07 | 2018-08-04 | ||
| EP4306648A3 (en) | 2014-05-19 | 2024-04-17 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice expressing human epo |
| WO2015196051A1 (en) | 2014-06-19 | 2015-12-23 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized programmed cell death 1 gene |
| RS63410B1 (sr) | 2014-11-24 | 2022-08-31 | Regeneron Pharma | Ne-humane životinje koje eksprimiraju humanizovani cd3 kompleks |
| BR112017010490A2 (pt) | 2014-12-05 | 2018-04-03 | Regeneron Pharma | roedor, polipeptídeo cd47, célula ou tecido de roedor isolado, célula-tronco emprionária de roedor, embrião de roedor, e, métodos de produzir um roedor, de fornecimento de um roedor, de enxerto de células humanas em um roedor, de avaliação de eficácia terapêutica de uma droga direcionada a células humanas e de avaliar as propriedades farmacocinéticas, de avaliar a toxicidade específica e inespecífica de uma droga direcionada ao cd47 humano. |
| LT3230320T (lt) | 2014-12-09 | 2021-01-11 | Regeneron Pharmaceuticals, Inc. | Gyvūnai, išskyrus žmogų, turintys humanizuotą diferenciacijos klasterio 274 geną |
| DK3280257T3 (da) | 2015-04-06 | 2023-09-04 | Regeneron Pharma | Humaniseret T-celle-formidlet immunrespons i ikke-humane dyr |
| LT3376857T (lt) | 2015-11-20 | 2021-06-25 | Regeneron Pharmaceuticals, Inc. | Gyvūnai, ne žmonės, turintys humanizuotą limfocitų aktyvavimo geną |
-
2016
- 2016-11-18 LT LTEP16810152.5T patent/LT3376857T/lt unknown
- 2016-11-18 WO PCT/US2016/062733 patent/WO2017087780A1/en not_active Ceased
- 2016-11-18 BR BR112018010158A patent/BR112018010158A2/pt not_active Application Discontinuation
- 2016-11-18 JP JP2018526188A patent/JP6997708B2/ja active Active
- 2016-11-18 HU HUE16810152A patent/HUE054612T2/hu unknown
- 2016-11-18 ES ES16810152T patent/ES2872799T3/es active Active
- 2016-11-18 SI SI201631205T patent/SI3376857T1/sl unknown
- 2016-11-18 AU AU2016358101A patent/AU2016358101B2/en active Active
- 2016-11-18 EP EP16810152.5A patent/EP3376857B1/en active Active
- 2016-11-18 RS RS20210623A patent/RS61866B1/sr unknown
- 2016-11-18 PT PT168101525T patent/PT3376857T/pt unknown
- 2016-11-18 HR HRP20210824TT patent/HRP20210824T1/hr unknown
- 2016-11-18 RU RU2018117944A patent/RU2745403C2/ru active
- 2016-11-18 CA CA3003786A patent/CA3003786C/en active Active
- 2016-11-18 DK DK16810152.5T patent/DK3376857T3/da active
- 2016-11-18 SM SM20210299T patent/SMT202100299T1/it unknown
- 2016-11-18 KR KR1020187016719A patent/KR102454546B1/ko active Active
- 2016-11-18 US US15/355,392 patent/US10306874B2/en active Active
- 2016-11-18 PL PL16810152T patent/PL3376857T3/pl unknown
- 2016-11-18 MX MX2018005389A patent/MX2018005389A/es unknown
- 2016-11-18 CN CN201680067496.1A patent/CN108366548B/zh active Active
- 2016-11-18 SG SG11201803409UA patent/SG11201803409UA/en unknown
- 2016-11-18 NZ NZ742447A patent/NZ742447A/en not_active IP Right Cessation
-
2018
- 2018-04-22 IL IL258841A patent/IL258841B/en active IP Right Grant
- 2018-04-24 ZA ZA2018/02717A patent/ZA201802717B/en unknown
-
2019
- 2019-04-18 US US16/387,664 patent/US11102961B2/en active Active
-
2021
- 2021-05-21 CY CY20211100443T patent/CY1124171T1/el unknown
- 2021-07-29 US US17/388,111 patent/US12096754B2/en active Active
-
2024
- 2024-08-13 US US18/802,201 patent/US20240397919A1/en active Pending